Movatterモバイル変換


[0]ホーム

URL:


WO2011049625A1 - Method for aflatoxin screening of products - Google Patents

Method for aflatoxin screening of products
Download PDF

Info

Publication number
WO2011049625A1
WO2011049625A1PCT/US2010/002804US2010002804WWO2011049625A1WO 2011049625 A1WO2011049625 A1WO 2011049625A1US 2010002804 WUS2010002804 WUS 2010002804WWO 2011049625 A1WO2011049625 A1WO 2011049625A1
Authority
WO
WIPO (PCT)
Prior art keywords
aflatoxin
composite
bins
sample
bin
Prior art date
Application number
PCT/US2010/002804
Other languages
French (fr)
Inventor
Mansour Samadpour
Original Assignee
Mansour Samadpour
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mansour SamadpourfiledCriticalMansour Samadpour
Publication of WO2011049625A1publicationCriticalpatent/WO2011049625A1/en

Links

Classifications

Definitions

Landscapes

Abstract

A method for screening a lot of product comprising multiple, individual bags or bins wherein a samples taken from each bag or bin are formed into a composite, which composite is tested for toxin or other contamination. If the test shows positive, the samples are then tested individually to determine which bag or bin is contaminated, thus permitting non-contaminated bags or bins to be released.

Description

METHOD FOR AFLATOXIN SCREENING OF PRODUCTS
The present invention relates to a method for avoiding waste of food and other products related to a positive test for the presence of aflatoxin and similar toxins.
Currently, testing for microbial toxins such as aflatoxin and other mycotoxins is conducted in a manner that results in rejection of the entire lot of the product. For instance pistachio and almond aflatoxin testing relies on collecting 5-10 kg of sample from 20-22 bins/bags of products, each containing about 2000 pounds of the product. The sample is then homogenized/blended and a small portion (150 grams) is subjected to ethanol extraction followed by cleanup and detection. Under the prior art, if the sample tests positive, all 20-22 bins/bags are typically destroyed, with economic loss to the producers.
In the current invention each bin/bag is sampled individually, each sample is
blended/homogenized individually, and a composite consisting of preferably equal volumes taken from each sample homogenate/blend is formed and subjected to the detection protocol. If the result is acceptable, then the entire group of bins/bags is accepted. However, if the levels of the toxin are higher than the accepted standards, then each bin/bag homogenate is tested separately, and any bin/bag for
l which the corresponding homogenate has a higher than acceptable limit is then excluded. A new composite is formed from bags/bins that have below acceptable limit levels of the toxin, and tested to issue a certificate of analysis. Alternatively, bags that have a mean average of toxin level falling below the acceptable limit for the lot can be used to form a composite and an additional test performed to verify the level of toxin in this composite. Alternatively the final composite may not need to be formed and tested. Instead an arithmetic mean of the bags that have suitable levels of toxins can be calculated to estimate a final level and issue a certificate based on individual bag/bin/test results.
In the following, "aflatoxin" is used as an exemplary toxin which may be deal with using the disclosed process. However, the process may just as well be used with other mycotoxins or other forms of contamination as needs dictate.
Brief Description of the Drawing
Fig. 1 is a flow diagram of the method disclosed herein.
Detailed Description
Fig. 1 shows test lot 1, which is a collection of bins 2 containing product 3, which may be food product such as nuts, including pistachios or almonds. Sampling device 4 is used to take a sample of product from each bin, each sample is homogenized by blending device 5, and placed in individual sample containers 6. A portion of the contents of each container 6 is then taken and placed in composite sample container 7. The contents of 7 are well mixed and subjected to aflatoxin testing process 8. Meanwhile, each container 6 and its remaining contents are stored in holding area 9. If the results of testing process 8 show aflatoxin at acceptable levels, then the entire test lot of bins is released for delivery to the customer. If results of testing process 8 show aflatoxin above acceptable limits in the test lot, then individual containers in holding area 9, each containing sample from a single bin 2, are tested to determine the level of aflatoxin present in individual bins 2. If a particular bin 2 is thus identified to have an above-acceptable level of aflatoxin, that bin is excluded from shipment.
Meanwhile, the remaining bins may be assembled into a lot that may be released to the customer, and a certificate of compliance with aflatoxin standards for the lot may be based upon the mathematically averaged results of the previous individual tests or upon additional testing of a composite formed from taking samples from such of the individual samples 6 as tested at acceptable levels.

Claims

Claim I claim:
1. A method for screening a test lot of product, which lot is comprised of a plurality containers such as bins or bags or the like, which method comprises the steps of:
a) taking at least one sample from each container;
b) taking a portion of each sample and combining these portions into a composite;
c) testing said composite for contamination;
d) in the event the testing of step c) indicates contamination, retesting the samples taken in step a) to determine the level of contamination in each container.
PCT/US2010/0028042009-10-202010-10-19Method for aflatoxin screening of productsWO2011049625A1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US27955709P2009-10-202009-10-20
US61/279,5572009-10-20

Publications (1)

Publication NumberPublication Date
WO2011049625A1true WO2011049625A1 (en)2011-04-28

Family

ID=43900599

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2010/002804WO2011049625A1 (en)2009-10-202010-10-19Method for aflatoxin screening of products

Country Status (1)

CountryLink
WO (1)WO2011049625A1 (en)

Citations (102)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3691016A (en)1970-04-171972-09-12Monsanto CoProcess for the preparation of insoluble enzymes
US3969287A (en)1972-12-081976-07-13Boehringer Mannheim GmbhCarrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier
US4179337A (en)1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4195128A (en)1976-05-031980-03-25Bayer AktiengesellschaftPolymeric carrier bound ligands
US4229537A (en)1978-02-091980-10-21New York UniversityPreparation of trichloro-s-triazine activated supports for coupling ligands
US4247642A (en)1977-02-171981-01-27Sumitomo Chemical Company, LimitedEnzyme immobilization with pullulan gel
US4289872A (en)1979-04-061981-09-15Allied CorporationMacromolecular highly branched homogeneous compound based on lysine units
US4301144A (en)1979-07-111981-11-17Ajinomoto Company, IncorporatedBlood substitute containing modified hemoglobin
US4330440A (en)1977-02-081982-05-18Development Finance Corporation Of New ZealandActivated matrix and method of activation
US4496689A (en)1983-12-271985-01-29Miles Laboratories, Inc.Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4640835A (en)1981-10-301987-02-03Nippon Chemiphar Company, Ltd.Plasminogen activator derivatives
US4670417A (en)1985-06-191987-06-02Ajinomoto Co., Inc.Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)1986-06-261988-12-13Takeda Chemical Industries, Ltd.Chemically modified protein with polyethyleneglycol
US4925673A (en)1986-08-181990-05-15Clinical Technologies Associates, Inc.Delivery systems for pharmacological agents encapsulated with proteinoids
WO1990005719A1 (en)1988-11-231990-05-31British Bio-Technology LimitedHydroxamic acid based collagenase inhibitors
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
US5229490A (en)1987-05-061993-07-20The Rockefeller UniversityMultiple antigen peptide system
WO1993021259A1 (en)1992-04-141993-10-28Cornell Research Foundation Inc.Dendritic based macromolecules and method of production
EP0606046A1 (en)1993-01-061994-07-13Ciba-Geigy AgArylsulfonamido-substituted hydroxamic acids
JPH08176070A (en)1994-12-191996-07-09Mitsubishi Chem Corp Didepside derivative and PI3 kinase inhibitor
JPH08175990A (en)1994-12-191996-07-09Mitsubishi Chem Corp PI3 kinase inhibitor and method for producing the same
WO1996027583A1 (en)1995-03-081996-09-12Pfizer Inc.Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en)1995-04-201996-10-24Pfizer Inc.Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
WO1997015658A1 (en)1995-10-261997-05-01Ludwig Institute For Cancer ResearchWortmannin phosphoinositide 3-kinase interaction site
EP0780386A1 (en)1995-12-201997-06-25F. Hoffmann-La Roche AgMatrix metalloprotease inhibitors
US5646176A (en)1992-12-241997-07-08Bristol-Myers Squibb CompanyPhosphonooxymethyl ethers of taxane derivatives
WO1998003516A1 (en)1996-07-181998-01-29Pfizer Inc.Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en)1996-08-231998-02-26Pfizer Inc.Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en)1997-01-061998-07-16Pfizer Inc.Cyclic sulfone derivatives
WO1998033768A1 (en)1997-02-031998-08-06Pfizer Products Inc.Arylsulfonylamino hydroxamic acid derivatives
WO1998034918A1 (en)1997-02-111998-08-13Pfizer Inc.Arylsulfonyl hydroxamic acid derivatives
WO1998034915A1 (en)1997-02-071998-08-13Pfizer Inc.N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1999002514A2 (en)1997-07-081999-01-21Bristol-Myers Squibb CompanyEpothilone derivatives
WO1999029667A1 (en)1997-12-051999-06-17Pfizer LimitedHydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en)1998-01-271999-07-28Pfizer LimitedMetalloprotease inhibitors
WO1999052910A1 (en)1998-04-101999-10-21Pfizer Products Inc.Bicyclic hydroxamic acid derivatives
WO1999052889A1 (en)1998-04-101999-10-21Pfizer Products Inc.(4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
US6262094B1 (en)1999-02-222001-07-17Bristol-Myers Squibb CompanyC-21 modified epothilones
JP2001247477A (en)2000-03-032001-09-11Teikoku Hormone Mfg Co Ltd Antitumor agent
WO2001081346A2 (en)2000-04-252001-11-01Icos CorporationInhibitors of human phosphatidyl-inositol 3-kinase delta
US6403588B1 (en)2000-04-272002-06-11Yamanouchi Pharmaceutical Co., Ltd.Imidazopyridine derivatives
WO2003035618A2 (en)2001-10-242003-05-01Iconix Pharmaceuticals, Inc.Modulators of phosphoinositide 3-kinase
WO2003034997A2 (en)2001-10-242003-05-01Iconix Pharmaceuticals, Inc.Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en)2001-10-302003-05-08Pharmacia CorporationHeteroaromatic carboxamide derivatives for the treatment of inflammation
US6608056B1 (en)2000-04-272003-08-19Yamanouchi Pharmaceutical Co., LtdFused heteroaryl derivatives
WO2004007491A1 (en)2002-07-102004-01-22Applied Research Systems Ars Holding N.V.Azolidinone-vinyl fused-benzene derivatives
WO2004006916A1 (en)2002-07-102004-01-22Applied Research Systems Ars Holding NvUse of compounds for increasing spermatozoa motility
WO2004017950A2 (en)2002-08-222004-03-04Piramed LimitedPhosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US6703414B2 (en)2001-09-142004-03-09Arizona Board Of Regents On Behalf Of The University Of ArizonaDevice and method for treating restenosis
US20040053946A1 (en)2001-01-162004-03-18Lackey Karen ElizabethCancer treatment method
EP1417976A1 (en)2001-07-262004-05-12Santen Pharmaceutical Co., Ltd.Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US20040092561A1 (en)2002-11-072004-05-13Thomas RuckleAzolidinone-vinyl fused -benzene derivatives
US20050043239A1 (en)2003-08-142005-02-24Jason DouangpanyaMethods of inhibiting immune responses stimulated by an endogenous factor
WO2006046035A1 (en)2004-10-252006-05-04Piramed LimitedPharmaceutical compounds
US20060115824A1 (en)*2004-04-152006-06-01Institute For Environmental Health, Inc.Trend analysis and statistical process control using multitargeted screening assays
US20060270673A1 (en)2003-04-242006-11-30Merck & Co., Inc.Inhibitors of akt activity
WO2007042810A1 (en)2005-10-112007-04-19Ludwig Institute For Cancer ResearchPyrimidine derivatives for the treatment of cancer
US20080039459A1 (en)2006-04-262008-02-14Plramed LimitedPhosphoinositide 3-kinase inhibitor compounds and methods of use
US20080076768A1 (en)2006-04-262008-03-27Piramed LimitedPharmaceutical compounds
WO2008070740A1 (en)2006-12-072008-06-12F.Hoffmann-La Roche AgPhosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008073785A2 (en)2006-12-072008-06-19Genentech, Inc.Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7534584B2 (en)*2004-08-062009-05-19Institute For Environmental Health, Inc.Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
WO2009105712A1 (en)2008-02-222009-08-27Irm LlcHeterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2009111547A1 (en)2008-03-042009-09-11Wyeth7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009109867A2 (en)2008-03-042009-09-11Natco Pharma LimitedCrystal form of phenylamino pyrimidine derivatives
WO2009111531A1 (en)2008-03-062009-09-11Bristol-Myers Squibb CompanyPyrrolotriazine kinase inhibitors
US7589101B2 (en)2005-08-162009-09-15Irm LlcCompounds and compositions as protein kinase inhibitors
US20090234132A1 (en)2006-05-232009-09-17Novartis Ag5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors
WO2009114870A2 (en)2008-03-142009-09-17Intellikine, Inc.Kinase inhibitors and methods of use
US20090233950A1 (en)2006-03-022009-09-17Frederic Henri JungQuinazoline derivatives
WO2009112565A1 (en)2008-03-132009-09-17Boehringer Ingelheim International GmbhThiazolyl-dihydro-indazoles
WO2009114874A2 (en)2008-03-142009-09-17Intellikine, Inc.Benzothiazole kinase inhibitors and methods of use
US20090233926A1 (en)2006-09-142009-09-17Astrazeneca2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US7592342B2 (en)2007-05-102009-09-22Smithkline Beecham CorporationQuinoxaline derivatives as PI3 kinase inhibitors
WO2009117482A1 (en)2008-03-192009-09-24Osi Pharmaceuticals, IncMtor inhibitor salt forms
US20090238828A1 (en)2004-08-142009-09-24Boehringer Ingelheim International GmbhCombinations for the Treatment of Diseases involving Cell Proliferation
US20090239936A1 (en)2006-05-152009-09-24Yoshikazu SugimotoProphylactic and Therapeutic Agent for Cancer
US20090239847A1 (en)2008-03-192009-09-24Ian BruceOrganic compounds
WO2009117097A1 (en)2008-03-192009-09-24Chembridge CorporationNovel tyrosine kinase inhibitors
US20090239859A1 (en)2008-02-292009-09-24Chua Peter CProtein kinase modulators
US7595330B2 (en)2005-09-062009-09-29Smithkline Beecham CorporationBenzimidazole thiophene compounds
US7595320B2 (en)2005-03-042009-09-29Aventis Pharma S.A.Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof
WO2009120094A2 (en)2008-03-272009-10-01Auckland Uniservices LimitedSubstituted pyrimidines and triazines and their use in cancer therapy
US20090247554A1 (en)2006-03-302009-10-01Takeda San Diego, Inc.Kinase inhibitors
US20090247567A1 (en)2008-03-312009-10-01Genentech, Inc.Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
US20090247538A1 (en)2004-10-252009-10-01Astex Therapeutics LimitedOrtho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
US20090247565A1 (en)2005-10-212009-10-01Jongwon LimTyrosine Kinase Inhibitors
US7598245B2 (en)2003-08-062009-10-06Vertex Pharmaceuticals IncorporatedAminotriazole compounds useful as inhibitors of protein kinases
US7601718B2 (en)2003-02-062009-10-13Vertex Pharmaceuticals IncorporatedCompositions useful as inhibitors of protein kinases
US7601724B2 (en)2002-09-042009-10-13Schering CorporationSubstituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20090258852A1 (en)2005-07-082009-10-15Arrington Kenneth LInhibitors of Checkpoint Kinases
WO2009126635A1 (en)2008-04-092009-10-15Abbott Laboratories2-amino-benzothiazole derivates useful as inhibitors of rock kinases
US7605155B2 (en)2002-09-042009-10-20Schering CorporationSubstituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605160B2 (en)2006-08-092009-10-20Bristol-Myers Squibb CompanyPyrrolotriazine kinase inhibitors
US20090263398A1 (en)2006-07-142009-10-22Astex Therapeutics LimitedPharmaceutical combinations
WO2009129211A1 (en)2008-04-162009-10-22Vertex Pharmaceuticals IncorporatedInhibitors of phosphatidylinositol 3-kinase
US20090263397A1 (en)2007-07-062009-10-22Buck Elizabeth ACombination anti-cancer therapy
WO2009129259A2 (en)2008-04-162009-10-22Takeda Pharmaceutical Company LimitedPolymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
US7608622B2 (en)2004-09-242009-10-27Janssen Pharmaceutica NvImidazo[4,5-b]pyrazinone inhibitors of protein kinases
US20090270445A1 (en)2006-01-182009-10-29Amgen Inc.Thiazole compounds and methods of use
US20090270430A1 (en)2005-10-072009-10-29Exelixix, Inc.Pyridopyrimidinone Inhibitors of Pl3Kalpha
US20090270621A1 (en)2003-08-142009-10-29Array Biopharma, Inc.Quinazoline analogs as receptor tyrosine kinase inhibitors

Patent Citations (118)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3691016A (en)1970-04-171972-09-12Monsanto CoProcess for the preparation of insoluble enzymes
US3969287A (en)1972-12-081976-07-13Boehringer Mannheim GmbhCarrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier
US4179337A (en)1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4195128A (en)1976-05-031980-03-25Bayer AktiengesellschaftPolymeric carrier bound ligands
US4330440A (en)1977-02-081982-05-18Development Finance Corporation Of New ZealandActivated matrix and method of activation
US4247642A (en)1977-02-171981-01-27Sumitomo Chemical Company, LimitedEnzyme immobilization with pullulan gel
US4229537A (en)1978-02-091980-10-21New York UniversityPreparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en)1979-04-061981-09-15Allied CorporationMacromolecular highly branched homogeneous compound based on lysine units
US4301144A (en)1979-07-111981-11-17Ajinomoto Company, IncorporatedBlood substitute containing modified hemoglobin
US4640835A (en)1981-10-301987-02-03Nippon Chemiphar Company, Ltd.Plasminogen activator derivatives
US4496689A (en)1983-12-271985-01-29Miles Laboratories, Inc.Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4670417A (en)1985-06-191987-06-02Ajinomoto Co., Inc.Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)1986-06-261988-12-13Takeda Chemical Industries, Ltd.Chemically modified protein with polyethyleneglycol
US4925673A (en)1986-08-181990-05-15Clinical Technologies Associates, Inc.Delivery systems for pharmacological agents encapsulated with proteinoids
US5229490A (en)1987-05-061993-07-20The Rockefeller UniversityMultiple antigen peptide system
WO1990005719A1 (en)1988-11-231990-05-31British Bio-Technology LimitedHydroxamic acid based collagenase inhibitors
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
WO1993021259A1 (en)1992-04-141993-10-28Cornell Research Foundation Inc.Dendritic based macromolecules and method of production
US5646176A (en)1992-12-241997-07-08Bristol-Myers Squibb CompanyPhosphonooxymethyl ethers of taxane derivatives
EP0606046A1 (en)1993-01-061994-07-13Ciba-Geigy AgArylsulfonamido-substituted hydroxamic acids
JPH08175990A (en)1994-12-191996-07-09Mitsubishi Chem Corp PI3 kinase inhibitor and method for producing the same
JPH08176070A (en)1994-12-191996-07-09Mitsubishi Chem Corp Didepside derivative and PI3 kinase inhibitor
US5863949A (en)1995-03-081999-01-26Pfizer IncArylsulfonylamino hydroxamic acid derivatives
WO1996027583A1 (en)1995-03-081996-09-12Pfizer Inc.Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en)1995-04-201999-01-19Pfizer IncArylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
WO1996033172A1 (en)1995-04-201996-10-24Pfizer Inc.Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
WO1997015658A1 (en)1995-10-261997-05-01Ludwig Institute For Cancer ResearchWortmannin phosphoinositide 3-kinase interaction site
EP0780386A1 (en)1995-12-201997-06-25F. Hoffmann-La Roche AgMatrix metalloprotease inhibitors
WO1998003516A1 (en)1996-07-181998-01-29Pfizer Inc.Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en)1996-08-231998-02-26Pfizer Inc.Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en)1997-01-061998-07-16Pfizer Inc.Cyclic sulfone derivatives
WO1998033768A1 (en)1997-02-031998-08-06Pfizer Products Inc.Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en)1997-02-071998-08-13Pfizer Inc.N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en)1997-02-111998-08-13Pfizer Inc.Arylsulfonyl hydroxamic acid derivatives
WO1999002514A2 (en)1997-07-081999-01-21Bristol-Myers Squibb CompanyEpothilone derivatives
WO1999029667A1 (en)1997-12-051999-06-17Pfizer LimitedHydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en)1998-01-271999-07-28Pfizer LimitedMetalloprotease inhibitors
WO1999052910A1 (en)1998-04-101999-10-21Pfizer Products Inc.Bicyclic hydroxamic acid derivatives
WO1999052889A1 (en)1998-04-101999-10-21Pfizer Products Inc.(4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
US6262094B1 (en)1999-02-222001-07-17Bristol-Myers Squibb CompanyC-21 modified epothilones
JP2001247477A (en)2000-03-032001-09-11Teikoku Hormone Mfg Co Ltd Antitumor agent
WO2001081346A2 (en)2000-04-252001-11-01Icos CorporationInhibitors of human phosphatidyl-inositol 3-kinase delta
US6800620B2 (en)2000-04-252004-10-05IcosInhibitors of human phosphatidylinositol 3-kinase delta
US6770641B2 (en)2000-04-272004-08-03Yamanouchi Pharmaceutical Co., Ltd.Fused heteroaryl derivatives
US7173029B2 (en)2000-04-272007-02-06Astellas Pharma Inc.Fused heteroaryl derivatives
US7037915B2 (en)2000-04-272006-05-02Astellas Pharma Inc.Fused heteroaryl derivatives
US6838457B2 (en)2000-04-272005-01-04Yamanouchi Pharmaceutical Co., Ltd.Fused heteroaryl derivatives
US6608056B1 (en)2000-04-272003-08-19Yamanouchi Pharmaceutical Co., LtdFused heteroaryl derivatives
US6608053B2 (en)2000-04-272003-08-19Yamanouchi Pharmaceutical Co., Ltd.Fused heteroaryl derivatives
US6403588B1 (en)2000-04-272002-06-11Yamanouchi Pharmaceutical Co., Ltd.Imidazopyridine derivatives
US6653320B2 (en)2000-04-272003-11-25Yamanouchi Pharmaceutical Co. Ltd.Imidazopyridine derivatives
US20040053946A1 (en)2001-01-162004-03-18Lackey Karen ElizabethCancer treatment method
EP1417976A1 (en)2001-07-262004-05-12Santen Pharmaceutical Co., Ltd.Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US6703414B2 (en)2001-09-142004-03-09Arizona Board Of Regents On Behalf Of The University Of ArizonaDevice and method for treating restenosis
WO2003035618A2 (en)2001-10-242003-05-01Iconix Pharmaceuticals, Inc.Modulators of phosphoinositide 3-kinase
US20030158212A1 (en)2001-10-242003-08-21Teri MeleseModulators of phosphoinositide 3-kinase
US20030149074A1 (en)2001-10-242003-08-07Teri MeleseModulators of phosphoinositide 3-kinase
WO2003034997A2 (en)2001-10-242003-05-01Iconix Pharmaceuticals, Inc.Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en)2001-10-302003-05-08Pharmacia CorporationHeteroaromatic carboxamide derivatives for the treatment of inflammation
WO2004006916A1 (en)2002-07-102004-01-22Applied Research Systems Ars Holding NvUse of compounds for increasing spermatozoa motility
WO2004007491A1 (en)2002-07-102004-01-22Applied Research Systems Ars Holding N.V.Azolidinone-vinyl fused-benzene derivatives
WO2004017950A2 (en)2002-08-222004-03-04Piramed LimitedPhosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7605155B2 (en)2002-09-042009-10-20Schering CorporationSubstituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7601724B2 (en)2002-09-042009-10-13Schering CorporationSubstituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20040092561A1 (en)2002-11-072004-05-13Thomas RuckleAzolidinone-vinyl fused -benzene derivatives
US7601718B2 (en)2003-02-062009-10-13Vertex Pharmaceuticals IncorporatedCompositions useful as inhibitors of protein kinases
US20060270673A1 (en)2003-04-242006-11-30Merck & Co., Inc.Inhibitors of akt activity
US7598245B2 (en)2003-08-062009-10-06Vertex Pharmaceuticals IncorporatedAminotriazole compounds useful as inhibitors of protein kinases
US20090270621A1 (en)2003-08-142009-10-29Array Biopharma, Inc.Quinazoline analogs as receptor tyrosine kinase inhibitors
US20050043239A1 (en)2003-08-142005-02-24Jason DouangpanyaMethods of inhibiting immune responses stimulated by an endogenous factor
US20060115824A1 (en)*2004-04-152006-06-01Institute For Environmental Health, Inc.Trend analysis and statistical process control using multitargeted screening assays
US7534584B2 (en)*2004-08-062009-05-19Institute For Environmental Health, Inc.Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
US20090258359A1 (en)*2004-08-062009-10-15Institute For Environmental HealthModular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
US20090238828A1 (en)2004-08-142009-09-24Boehringer Ingelheim International GmbhCombinations for the Treatment of Diseases involving Cell Proliferation
US7608622B2 (en)2004-09-242009-10-27Janssen Pharmaceutica NvImidazo[4,5-b]pyrazinone inhibitors of protein kinases
WO2006046040A1 (en)2004-10-252006-05-04Piramed LimitedPharmaceutical compounds
US20080207611A1 (en)2004-10-252008-08-28Plramed LimitedPharmaceutical compounds
WO2006046035A1 (en)2004-10-252006-05-04Piramed LimitedPharmaceutical compounds
WO2006046031A1 (en)2004-10-252006-05-04Piramed LimitedPharmaceutical compounds
US20090247538A1 (en)2004-10-252009-10-01Astex Therapeutics LimitedOrtho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
US7595320B2 (en)2005-03-042009-09-29Aventis Pharma S.A.Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof
US20090258852A1 (en)2005-07-082009-10-15Arrington Kenneth LInhibitors of Checkpoint Kinases
US7589101B2 (en)2005-08-162009-09-15Irm LlcCompounds and compositions as protein kinase inhibitors
US7595330B2 (en)2005-09-062009-09-29Smithkline Beecham CorporationBenzimidazole thiophene compounds
US20090270430A1 (en)2005-10-072009-10-29Exelixix, Inc.Pyridopyrimidinone Inhibitors of Pl3Kalpha
WO2007042806A1 (en)2005-10-112007-04-19Ludwig Institute For Cancer ResearchPyrimidine derivatives for the treatment of cancer
WO2007042810A1 (en)2005-10-112007-04-19Ludwig Institute For Cancer ResearchPyrimidine derivatives for the treatment of cancer
US20090247565A1 (en)2005-10-212009-10-01Jongwon LimTyrosine Kinase Inhibitors
US20090270445A1 (en)2006-01-182009-10-29Amgen Inc.Thiazole compounds and methods of use
US20090233950A1 (en)2006-03-022009-09-17Frederic Henri JungQuinazoline derivatives
US20090247554A1 (en)2006-03-302009-10-01Takeda San Diego, Inc.Kinase inhibitors
US20080076768A1 (en)2006-04-262008-03-27Piramed LimitedPharmaceutical compounds
US20080039459A1 (en)2006-04-262008-02-14Plramed LimitedPhosphoinositide 3-kinase inhibitor compounds and methods of use
US20090239936A1 (en)2006-05-152009-09-24Yoshikazu SugimotoProphylactic and Therapeutic Agent for Cancer
US20090234132A1 (en)2006-05-232009-09-17Novartis Ag5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors
US20090263398A1 (en)2006-07-142009-10-22Astex Therapeutics LimitedPharmaceutical combinations
US7605160B2 (en)2006-08-092009-10-20Bristol-Myers Squibb CompanyPyrrolotriazine kinase inhibitors
US20090233926A1 (en)2006-09-142009-09-17Astrazeneca2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008073785A2 (en)2006-12-072008-06-19Genentech, Inc.Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008070740A1 (en)2006-12-072008-06-12F.Hoffmann-La Roche AgPhosphoinositide 3-kinase inhibitor compounds and methods of use
US7592342B2 (en)2007-05-102009-09-22Smithkline Beecham CorporationQuinoxaline derivatives as PI3 kinase inhibitors
US20090263397A1 (en)2007-07-062009-10-22Buck Elizabeth ACombination anti-cancer therapy
WO2009105712A1 (en)2008-02-222009-08-27Irm LlcHeterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
US20090239859A1 (en)2008-02-292009-09-24Chua Peter CProtein kinase modulators
WO2009109867A2 (en)2008-03-042009-09-11Natco Pharma LimitedCrystal form of phenylamino pyrimidine derivatives
WO2009111547A1 (en)2008-03-042009-09-11Wyeth7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009111531A1 (en)2008-03-062009-09-11Bristol-Myers Squibb CompanyPyrrolotriazine kinase inhibitors
WO2009112565A1 (en)2008-03-132009-09-17Boehringer Ingelheim International GmbhThiazolyl-dihydro-indazoles
WO2009114874A2 (en)2008-03-142009-09-17Intellikine, Inc.Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en)2008-03-142009-09-17Intellikine, Inc.Kinase inhibitors and methods of use
WO2009117097A1 (en)2008-03-192009-09-24Chembridge CorporationNovel tyrosine kinase inhibitors
WO2009117482A1 (en)2008-03-192009-09-24Osi Pharmaceuticals, IncMtor inhibitor salt forms
US20090239847A1 (en)2008-03-192009-09-24Ian BruceOrganic compounds
WO2009120094A2 (en)2008-03-272009-10-01Auckland Uniservices LimitedSubstituted pyrimidines and triazines and their use in cancer therapy
US20090247567A1 (en)2008-03-312009-10-01Genentech, Inc.Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
WO2009126635A1 (en)2008-04-092009-10-15Abbott Laboratories2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2009129211A1 (en)2008-04-162009-10-22Vertex Pharmaceuticals IncorporatedInhibitors of phosphatidylinositol 3-kinase
WO2009129259A2 (en)2008-04-162009-10-22Takeda Pharmaceutical Company LimitedPolymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor

Non-Patent Citations (91)

* Cited by examiner, † Cited by third party
Title
"Basic and Clinical Pharmacology", 2003, MCGRAW HILL
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Goodman and Gilman's The Pharmacological Basis of Therapeutics", 1996, pages: 11 - 16
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON
"Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS.
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
ABID ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 24, 2004, pages 294 - 300
AOUDJIT ET AL., J. IMMUNOL., vol. 161, 1998, pages 2333 - 2338
B. MARKMAN, ANNALS OF ONCOLOGY ADVANCE ACCESS, August 2009 (2009-08-01)
BACKER JM., BIOCHEM J, vol. 410, 2008, pages 1 - 17
BENNETT ET AL., J. PHARMACOL. EXP. THER., vol. 280, 1997, pages 988 - 1000
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185
BLOEMEN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 153, 1996, pages 521 - 529
BLUME- JENSEN P ET AL., NATURE, vol. 411, no. 6835, 2001, pages 355 - 365
BOWES ET AL., EXP. NEUROL., vol. 119, 1993, pages 215 - 219
BURGERING ET AL., NATURE, vol. 376, 1995, pages 599 - 602
CARNERO A, CURR CANCER DRUG TARGETS, vol. 8, 2008, pages 187 - 98
CHIOSIS ET AL., BIOORGANIC & MED. CHEM. LETT., vol. 11, 2001, pages 909 - 913
CHOPP ET AL., STROKE, vol. 25, 1994, pages 869 - 875
CLARK ET AL., NEUROSURG., vol. 75, 1991, pages 623 - 627
COSIMI ET AL., J. IMMUNOL., vol. 144, 1990, pages 4604 - 4612
COUSSENS; WERB, NATURE, vol. 420, 2002, pages 860 - 867
DEMEESTER ET AL., TRANSPLANTATION, vol. 62, 1996, pages 1477 - 1485
ENGELMAN JA, NAT REV GENET, vol. 7, 2006, pages 606 - 19
EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 9, 2009, pages 1265 - 12 77
FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO.
FRASER ET AL., SCIENCE, vol. 251, 1991, pages 313 - 16
FRUMAN ET AL., ANN REV BIOCHEM, vol. 67, 1998, pages 481 - 507
GORCZYNSKI; WOJCIK, J. IMMUNOL., vol. 152, 1994, pages 2011 - 2019
GROSS ET AL., SCIENCE, vol. 218, 1998, pages 703 - 706
GUTE ET AL., MOL. CELL BIOCHEM., vol. 179, 1998, pages 169 - 187
HALLAHAN ET AL., PROC. NATL. ACAD. SCI (USA), vol. 94, 1997, pages 6432 - 6437
HALLORAN ET AL., ARTHRITIS RHEUM., vol. 39, 1996, pages 810 - 819
HARARI ET AL., ONCOGENE, vol. 19, 2000, pages 6102 - 6114
HARNING ET AL., TRANSPLANTATION, vol. 52, 1991, pages 842 - 845
HARTMAN ET AL., CARDIOVASC. RES., vol. 30, 1995, pages 47 - 54
HASAGAWA ET AL., INT. IMMUNOL., vol. 6, 1994, pages 831 - 838
HE ET AL., OPTHALMOL. VIS. SCI., vol. 35, 1994, pages 3218 - 3225
HERROLD ET AL., CELL IMMUNOL., vol. 157, 1994, pages 489 - 500
HIGUCHI ET AL.: "Prodrugs as Novel Delivery Systems", ASCD SYMPOSIUM SERIES, vol. 14
HORGAN ET AL., AM. J. PHYSIOL., vol. 261, 1991, pages H1578 - H1584
ISOBE ET AL., SCIENCE, vol. 255, 1992, pages 1125 - 1127
KAKIMOTO ET AL., CELL. IMMUNOL., vol. 142, 1992, pages 326 - 337
KAUFFMANN-ZEH ET AL., NATURE, vol. 385, 1997, pages 544 - 548
KAWASAKI ET AL., J. IMMUNOL., vol. 150, 1993, pages 1074 - 1083
KNOERZER ET AL., TOXICOL. PATHOL., vol. 25, 1997, pages 13 - 19
LEMMON ET AL., TRENDS CELL BIOL, vol. 7, 1997, pages 237 - 42
MA ET AL., ONCOGENE, vol. 19, 2000, pages 2739 - 2744
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS
MATTER A., DRUG DISC TECHNOL, vol. 6, 2001, pages 1005 - 1024
MULLIGAN ET AL., J. IMMUNOL., vol. 154, 1995, pages 1350 - 1363
MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC.
NAGASE ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 154, 1996, pages 504 - 510
NAKAO ET AL., MUSCLE NERVE, vol. 18, 1995, pages 93 - 102
NATHAN T., MOL CANCER THER., vol. 8, no. 1, January 2009 (2009-01-01)
NICHOLSON; ANDERSON, CELLULAR SIGNALLING, vol. H, 2002, pages 381 - 395
OPPENHEIMER-MARKS ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1261 - 1272
OSHIRO ET AL., STROKE, vol. 28, 1997, pages 2031 - 2038
PAGES ET AL., NATURE, vol. 369, 1994, pages 327 - 29
PANAYOTOU ET AL., TRENDS CELL BIOL, vol. 2, 1992, pages 358 - 60
PANES ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 1761 - 1769
PARKER ET AL., CURRENT BIOLOGY, vol. 5, 1995, pages 577 - 99
PHILLIPS ET AL., CANCER, vol. 83, 1998, pages 41
PHILP ET AL., CANCER RESEARCH, vol. 61, 2001, pages 7426 - 7429
PIXU LIU, NATURE REVIEWS DRUG DISCOVERY, vol. 8, 2009, pages 627 - 644
RAMEH ET AL., J. BIOL CHEM, vol. 274, 1999, pages 8347 - 8350
REMINGTON'S PHARMACEUTICAL SCIENCES, pages 1435 - 1712
ROMINA MARONE, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185
RUDD, IMMUNITY, vol. 4, 1996, pages 527 - 34
SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554
SAWYER, EXPERT OPINION INVESTIG. DRUGS, vol. JJ., 2004, pages 1 - 19
SCHIMMER ET AL., J. IMMUNOL., vol. 160, 1998, pages 1466 - 1477
SHAYESTEH ET AL., NATURE GENETICS., vol. 21, 1999, pages 99 - 102
SIMPSON; PARSONS, EXP. CELL RES., vol. 264, 2001, pages 29 - 41
STERNMARK ET AL., J CELL SCI, vol. 112, 1999, pages 4175 - 83
T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
TALENTO ET AL., TRANSPLANTATION, vol. 55, 1993, pages 418 - 422
TAMIYA ET AL., IMMUNOPHARMACOLOGY, vol. 29, 1995, pages 53 - 63
TANAKA ET AL., J. IMMUNOL., vol. 151, 1993, pages 5088 - 5095
VANHAESEBROECK B, TRENDS BIOCHEM SCI, vol. 30, 2005, pages 194 - 204
VARA ET AL., CANCER TREATMENT REVIEWS, vol. 30, 2004, pages 193 - 204
VIVANCO ET AL., NATURE REV. CANCER, vol. 2, 2002, pages 489
VIVANCO; SAWYERS, NATURE REVIEWS CANCER, vol. 2, 2002, pages 489 - 501
VLAHOS ET AL., J. BIOL. CHEM., vol. 269, no. 7, 1994, pages 5241 - 5248
WALKER ET AL., MOL. CELL, vol. 6, 2000, pages 909 - 919
WEGNER ET AL., LUNG, vol. 170, 1992, pages 267 - 279
WEGNER ET AL., SCIENCE, vol. 247, 1990, pages 456 - 459
WHITMAN ET AL., NATURE, vol. 332, 1988, pages 664
YAO ET AL., SCIENCE, vol. 267, 1995, pages 2003 - 05
ZENG ET AL., TRANSPLANTATION, vol. 58, 1994, pages 681 - 689

Similar Documents

PublicationPublication DateTitle
Quevauviller et al.Certified reference material for the quality control of EDTA-and DTPA-extractable trace metal contents in calcareous soil (CRM 600)
Benoist et al.Biasing in the galaxy distribution
De SaegerDetermining mycotoxins and mycotoxigenic fungi in food and feed
WO2006026466A3 (en)Automated seed sampler and methods of sampling, testing and bulking seeds
Vanheule et al.The compositional mosaic of Fusarium species and their mycotoxins in unprocessed cereals, food and feed products in Belgium
Tittlemier et al.Sampling of cereals and cereal-based foods for the determination of ochratoxin A: an overview
Schuller et al.A review of sampling plans and collaboratively studied methods of analysis for aflatoxins
US20120090410A1 (en)Method for aflatoxin screening of products
WO2011049625A1 (en)Method for aflatoxin screening of products
WO2002103329A3 (en)Apparatus and method for determining the dispersibility of a product in particulate form
Sfeir et al.An evaluation of municipal solid waste composition bias sources
Stroka et al.Novel sampling methods for the analysis of mycotoxins and the combination with spectroscopic methods for the rapid evaluation of deoxynivalenol contamination
Tittlemier et al.By-products of grain cleaning: an opportunity for rapid sampling and screening of wheat for mycotoxins
Maestroni et al.Sampling strategies to control mycotoxins
CokerDesign of sampling plans for determination of mycotoxins in foods and feeds
US20130199287A1 (en)Auto Micronaire
Haarer et al.Early enrichment and restitution of the peripheral blood treg pool is associated with rejection-free stable immunosuppression after liver transplantation
Whitaker et al.Performance of sampling plans to determine aflatoxin in farmers’ stock peanut lots by measuring aflatoxin in high-risk-grade components
Daun et al.How green is green? Sampling and perception in assessing green seeds and chlorophyll in canola
Gu et al.Preparation and Certification of High‐Grade Gold Ore Reference Materials (GAu 19‐22)
Falconer et al.Automated color sorting of hand-harvested Chardonnay
Masoumi et al.Design, construction and evaluation of an automatic apple grading system
CN106950238A (en)A kind of Fast nondestructive evaluation and the method for filtering out low cadmium rice or brown rice simultaneously
Morais et al.The use of light microscopy in a study of extraneous matter and authenticity of guava, strawberry and grape jams
Park et al.Performance of three pneumatic probe samplers and four analytical methods used to estimate aflatoxins in bulk cottonseed

Legal Events

DateCodeTitleDescription
121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:10825332

Country of ref document:EP

Kind code of ref document:A1

122Ep: pct application non-entry in european phase

Ref document number:10825332

Country of ref document:EP

Kind code of ref document:A1


[8]ページ先頭

©2009-2025 Movatter.jp